TSXV: FIRE
TORONTO, Jan. 8, 2018
/CNW/ - The Supreme Cannabis Company, Inc. ("Supreme"
or the "Company") (TSXV: FIRE) is pleased to
announce the addition of Ms. Sony Gokhale, BBA, LLB, as the
Company's General Counsel. Ms. Gokhale was most recently a
senior member of the Commercial and Technology group at
Osler, Hoskin & Harcourt, LLP
in Toronto, Ontario.
"Our business is driven by a commitment to quality. The quality
of our products, the quality of our facility and, most of all, the
quality of our leadership team," said John
Fowler, CEO of Supreme. "Since inception, Supreme has
been focused on developing 7ACRES into a leading cultivator of
premium cannabis flower for the domestic medical and recreational
markets. The next chapter for Supreme is to identify and execute on
opportunities to leverage our success with 7ACRES into additional
business undertakings here in Canada and abroad. Supreme is pleased to
welcome Ms. Gokhale to our team as we embark on this next
chapter."
Prior to joining Supreme, Ms. Gokhale's practice included
advising on general corporate and commercial matters with a focus
on assisting regulated and non-regulated companies with the launch
of new products and services in the Canadian market. Additionally,
Ms. Gokhale has provided ongoing advice to leading Canadian and
international companies on strategic commercial contracting
issues. Prior to joining Osler, Ms. Gokhale was senior counsel for
BlackBerry where she negotiated various complex offshore
service and distribution agreements in over twenty countries.
The Company granted 500,000 stock options (each an
"Option") to Ms. Gokhale pursuant to the Company's Amended
and Restated Incentive Stock Option Plan (the "Plan"). Each
Option has an exercise price of $3.05
and is exercisable into one common share , subject to certain
vesting conditions and the terms and conditions of the Plan, and
expire on January 7, 2023.
About Supreme
Supreme is a Canadian publicly traded company committed to
becoming a leading cultivator and distributor of sun grown cannabis
through its wholly-owned subsidiary 7ACRES. 7ACRES is a federally
licensed producer of medical cannabis pursuant to the ACMPR
operating inside a 342,000 sq. ft. Hybrid Greenhouse facility. The
Hybrid Greenhouse combines the best technology of indoor production
with the efficiencies and sustainability of a greenhouse, in a
single large-format production footprint. Please visit
www.supreme.ca and www.7acres.com for more information.
Forward-Looking Information
Certain statements made in this press release may constitute
forward-looking information under applicable securities laws. These
statements may relate to anticipated events or results and include,
but are not limited to, all statements that are not historical
facts. Particularly, information regarding our expectations of
future results, targets, performance achievements, prospects or
opportunities is forward-looking information. Often, but not
always, forward-looking statements can be identified by the use of
forward-looking terminology such as "may" "will", "expect",
"believe", "estimate", "plan", "could", "should", "would",
"outlook", "forecast", "anticipate", "foresee", "continue" or the
negative of these terms or variations of them or similar
terminology. Forward-looking statements are current as of the date
they are made and are based on applicable estimates and assumptions
made by us at the relevant time in light of our experience and
perception of historical trends, current conditions and expected
future developments, as well as other factors that we believe are
appropriate and reasonable in the circumstances. However, we do not
undertake to update any such forward-looking information whether as
a result of new information, future events or otherwise, except as
required under applicable securities laws in Canada. There can be no assurance that such
estimates and assumptions will prove to be correct. Many
factors could cause our actual results, level of activity,
performance or achievements or future events or developments to
differ materially from those expressed or implied by the
forward-looking statements, including, without limitation, the
factors discussed in the "Risks and Uncertainties" section of the
Company's Management's Discussion & Analysis dated November 27, 2017 ("MD&A"). A copy of the
MD&A and the Company's other publicly filed documents can be
accessed under the Company's profile on SEDAR at www.sedar.com. The
Company cautions that the list of risk factors and uncertainties
described in the MD&A is not exhaustive and other factors could
also adversely affect its results. Readers are urged to consider
the risks, uncertainties and assumptions carefully in evaluating
the forward-looking information and are cautioned not to place
undue reliance on such information.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Supreme Pharmaceuticals Inc.